← Back to Methodology
RQS Scoring Log

Pinealon

Longevity & Cellular Aging· Animal / In Vitro· Scored May 2026· View compound profile →
10 /100
Insufficient Evidence
7 dimensions · 100 points total · Methodology by PeptideClear
Dimension Breakdown
DimensionScoring NotesScore
Study Design
Primarily animal (rat) and in vitro studies. Same Khavinson group origin as Epitalon. Very limited human data — a few small observational reports in Russian literature. Animal/in vitro categorization is accurate.
 2 / 25
Sample Size
No meaningful human intervention data.
 0 / 20
Replication
Almost exclusively Khavinson/St. Petersburg Institute. Even more concentrated than Epitalon in terms of independent replication.
 2 / 20
Journal Impact Factor
Published in Russian pharmacology and gerontology journals with minimal Western IF. Some papers in Bulletin of Experimental Biology and Medicine.
 4 / 15
Funding Independence
Russian government/academic funded but single-institution dominance reduces confidence.
 1 / 10
Population Diversity
Animal/in vitro. Not applicable.
 0 / 5
Researcher h-Index
Same Khavinson group — moderate Russian database h-Index but lowest compound in catalog for evidence quality overall.
 1 / 5
Animal Only Note
This score reflects evidence in humans. Animal and in vitro evidence may be substantially stronger than the score suggests — this compound has not yet been studied in human trials.
Russian Literature Note
A significant portion of evidence for this compound is published in Russian-language journals. Lower Journal Impact Factor scores reflect the publishing system, not necessarily the quality of the underlying science.
Scored by the PeptideClear editorial team using publicly available literature. Sources: PubMed (study design, sample size, replication) · ScimagoJR (journal impact factor) · Google Scholar (researcher h-Index) · Primary papers (funding disclosure). Scores are reviewed as new research is published.